<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:59:56Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4748308" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:4748308</identifier><datestamp>2016-02-19</datestamp><setSpec>ancltransneuro</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Clin Transl Neurol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2328-9503</journal-id>
      <journal-id journal-id-type="publisher-id">ACN3</journal-id>
      <journal-title-group>
        <journal-title>Annals of Clinical and Translational Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2328-9503</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC4748308</article-id>
      <article-id pub-id-type="pmcid">PMC4748308</article-id>
      <article-id pub-id-type="pmc-uid">4748308</article-id>
      <article-id pub-id-type="pmid">26900580</article-id>
      <article-id pub-id-type="doi">10.1002/acn3.276</article-id>
      <article-id pub-id-type="publisher-id">ACN3276</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pathogenic mechanism of recurrent mutations of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN8A</styled-content></styled-content> in epileptic encephalopathy</article-title>
        <alt-title alt-title-type="left-running-head">J. L. Wagnon <italic>et al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="acn3276-cr-0001" contrib-type="author">
          <name>
            <surname>Wagnon</surname>
            <given-names>Jacy L.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0002" contrib-type="author">
          <name>
            <surname>Barker</surname>
            <given-names>Bryan S.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0003" contrib-type="author">
          <name>
            <surname>Hounshell</surname>
            <given-names>James A.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0004" contrib-type="author">
          <name>
            <surname>Haaxma</surname>
            <given-names>Charlotte A.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0005" contrib-type="author">
          <name>
            <surname>Shealy</surname>
            <given-names>Amy</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0006" contrib-type="author">
          <name>
            <surname>Moss</surname>
            <given-names>Timothy</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0007" contrib-type="author">
          <name>
            <surname>Parikh</surname>
            <given-names>Sumit</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0008" contrib-type="author">
          <name>
            <surname>Messer</surname>
            <given-names>Ricka D.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0009" contrib-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>Manoj K.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="acn3276-cr-0010" contrib-type="author" corresp="yes">
          <name>
            <surname>Meisler</surname>
            <given-names>Miriam H.</given-names>
          </name>
          <xref ref-type="aff" rid="acn3276-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="acn3276-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Human Genetics</named-content>
        <institution>University of Michigan</institution>
        <named-content content-type="city">Ann Arbor</named-content>
        <named-content content-type="country-part">Michigan</named-content>
      </aff>
      <aff id="acn3276-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Department of Anesthesiology and Neuroscience Graduate Program</named-content>
        <institution>University of Virginia Health System</institution>
        <named-content content-type="city">Charlottesville</named-content>
        <named-content content-type="country-part">Virginia</named-content>
      </aff>
      <aff id="acn3276-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatric Neurology</named-content>
        <institution>Radboud University</institution>
        <named-content content-type="city">Nijmegen</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="acn3276-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <institution>Cleveland Clinic Genomic Medicine Institute</institution>
        <named-content content-type="city">Cleveland</named-content>
        <named-content content-type="country-part">Ohio</named-content>
      </aff>
      <aff id="acn3276-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatric Neurology</named-content>
        <institution>Cleveland Clinic</institution>
        <named-content content-type="city">Cleveland</named-content>
        <named-content content-type="country-part">Ohio</named-content>
      </aff>
      <aff id="acn3276-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatric Neurology</named-content>
        <institution>Johns Hopkins Medical Institute</institution>
        <named-content content-type="city">Baltimore</named-content>
        <named-content content-type="country-part">Maryland</named-content>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Miriam H. Meisler, 4909 Buhl, University of Michigan, Ann Arbor, MI 48109â5618. Tel: 734â763â5546; Fax: 734â763â9691; Eâmail: <email>meislerm@med.umich.edu</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <volume>3</volume>
      <issue>2</issue>
      <issue-id pub-id-type="doi">10.1111/acn3.2016.3.issue-2</issue-id>
      <fpage>114</fpage>
      <lpage>123</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 American Neurological Association <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2015 The Authors. <italic>Annals of Clinical and Translational Neurology</italic> published by Wiley Periodicals, Inc on behalf of American Neurological Association.</copyright-statement>
        <license license-type="creativeCommonsBy-nc-nd">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons AttributionâNonCommercialâNoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is nonâcommercial and no modifications or adaptations are made.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ACN3-3-114.pdf"/>
      <abstract abstract-type="main" id="acn3276-abs-0001">
        <title>Abstract</title>
        <sec id="acn3276-sec-0001">
          <title>Objective</title>
          <p>The early infantile epileptic encephalopathy type 13 (<styled-content style="fixed-case">EIEE</styled-content>13, <styled-content style="fixed-case">OMIM</styled-content> #614558) results from de novo missense mutations of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN8A</styled-content></styled-content> encoding the voltageâgated sodium channel Na<sub>v</sub>1.6. More than 20% of patients have recurrent mutations in residues Arg1617 or Arg1872. Our goal was to determine the functional effects of these mutations on channel properties.</p>
        </sec>
        <sec id="acn3276-sec-0002">
          <title>Methods</title>
          <p>Clinical exome sequencing was carried out on patients with earlyâonset seizures, developmental delay, and cognitive impairment. Two mutations identified here, p.Arg1872Leu and p.Arg1872Gln, and two previously identified mutations, p.Arg1872Trp and p.Arg1617Gln, were introduced into Na<sub>v</sub>1.6 <styled-content style="fixed-case">cDNA</styled-content>, and effects on electrophysiological properties were characterized in transfected ND7/23 cells. Interactions with <styled-content style="fixed-case">FGF</styled-content>14, Gâprotein subunit G<italic>Î²Î³</italic>, and sodium channel subunit <italic>Î²</italic>1 were assessed by coimmunoprecipitation.</p>
        </sec>
        <sec id="acn3276-sec-0003">
          <title>Results</title>
          <p>We identified two patients with the novel mutation p.Arg1872Leu and one patient with the recurrent mutation p.Arg1872Gln. The three mutations of Arg1872 and the mutation of Arg1617 all impaired the sodium channel transition from open state to inactivated state, resulting in channel hyperactivity. Other observed abnormalities contributing to elevated channel activity were increased persistent current, increased peak current density, hyperpolarizing shift in voltage dependence of activation, and depolarizing shift in steadyâstate inactivation. Protein interactions were not affected.</p>
        </sec>
        <sec id="acn3276-sec-0004">
          <title>Interpretation</title>
          <p>Recurrent mutations at Arg1617 and Arg1872 lead to elevated Na<sub>v</sub>1.6 channel activity by impairing channel inactivation. Channel hyperactivity is the major pathogenic mechanism for gainâofâfunction mutations of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN8A</styled-content></styled-content>. <styled-content style="fixed-case">EIEE</styled-content>13 differs mechanistically from Dravet syndrome, which is caused by lossâofâfunction mutations of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN1A</styled-content></styled-content>. This distinction has important consequences for selection of antiepileptic drugs and the development of geneâ and mutationâspecific treatments.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>National Institutes of Health</funding-source>
          <award-id>R01âNS34509</award-id>
          <award-id>R01âNS075157</award-id>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="10"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>acn3276</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>February 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:10.02.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="acn3276-sec-0005">
      <title>Introduction</title>
      <p>Early infantile epileptic encephalopathy type 13 (EIEE13, OMIM # 614558) is a newly recognized syndrome caused by de novo missense mutations of <italic>SCN8A</italic>. Clinical features include seizure onset before 18 months of age, intellectual disability, and developmental delay.<xref rid="acn3276-bib-0001" ref-type="ref">1</xref>, <xref rid="acn3276-bib-0002" ref-type="ref">2</xref>, <xref rid="acn3276-bib-0003" ref-type="ref">3</xref>, <xref rid="acn3276-bib-0004" ref-type="ref">4</xref>, <xref rid="acn3276-bib-0005" ref-type="ref">5</xref> Movement disorders are common and 50% of affected individuals are nonambulatory.<xref rid="acn3276-bib-0001" ref-type="ref">1</xref>, <xref rid="acn3276-bib-0003" ref-type="ref">3</xref>, <xref rid="acn3276-bib-0006" ref-type="ref">6</xref>, <xref rid="acn3276-bib-0007" ref-type="ref">7</xref>, <xref rid="acn3276-bib-0008" ref-type="ref">8</xref>, <xref rid="acn3276-bib-0009" ref-type="ref">9</xref>, <xref rid="acn3276-bib-0010" ref-type="ref">10</xref>, <xref rid="acn3276-bib-0011" ref-type="ref">11</xref>, <xref rid="acn3276-bib-0012" ref-type="ref">12</xref> SUDEP (sudden unexpected death in epilepsy) is reported in 10% of cases.<xref rid="acn3276-bib-0001" ref-type="ref">1</xref>, <xref rid="acn3276-bib-0002" ref-type="ref">2</xref>, <xref rid="acn3276-bib-0004" ref-type="ref">4</xref>, <xref rid="acn3276-bib-0005" ref-type="ref">5</xref>
</p>
      <p>
<italic>SCN8A</italic> encodes the poreâforming voltageâgated sodium channel subunit Na<sub>v</sub>1.6, which is widely expressed in neurons of the CNS and PNS.<xref rid="acn3276-bib-0013" ref-type="ref">13</xref> Nav1.6 is concentrated at the axon initial segment and at nodes of Ranvier.<xref rid="acn3276-bib-0014" ref-type="ref">14</xref>, <xref rid="acn3276-bib-0015" ref-type="ref">15</xref> Na<sub>v</sub>1.6 is composed of four homologous domains with six transmembrane segments each, and the cytoplasmic Nâterminal and Câterminal domains (Fig. <xref rid="acn3276-fig-0001" ref-type="fig">1</xref>A).</p>
      <fig fig-type="Figure" xml:lang="en" id="acn3276-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Recurrent mutations of arginine residues 1617 and 1872 in <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN8A</styled-content></styled-content>. (A) Fourâdomain structures of the voltageâgated sodium channel <italic>Î±</italic> subunit. The positions of the recurrently mutated residues Arg1617 (the outermost charged residue in the S4 transmembrane segment of domain IV) and Arg1872 (near the middle of the cytoplasmic Câterminal domain) are shown. (B) CpG mutation hot spots in the codons for Arg1617 and Arg1872.</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="ACN3-3-114-g001"/>
      </fig>
      <p>Two amino acid residues, Arg1617 and Arg1872, are the sites of mutation in 20% of EIEE13. Arg1617 is located in the voltageâresponsive S4 transmembrane segment of domain IV (Fig. <xref rid="acn3276-fig-0001" ref-type="fig">1</xref>A). The substitution p.Arg1617Gln has occurred in five unrelated individuals.<xref rid="acn3276-bib-0001" ref-type="ref">1</xref>, <xref rid="acn3276-bib-0002" ref-type="ref">2</xref>, <xref rid="acn3276-bib-0003" ref-type="ref">3</xref>, <xref rid="acn3276-bib-0016" ref-type="ref">16</xref>, <xref rid="acn3276-bib-0017" ref-type="ref">17</xref> Arg1872 is located in the cytoplasmic Câterminal domain (Fig. <xref rid="acn3276-fig-0001" ref-type="fig">1</xref>A). Two missense mutations of Arg1872 were described in seven patients<xref rid="acn3276-bib-0001" ref-type="ref">1</xref>, <xref rid="acn3276-bib-0003" ref-type="ref">3</xref>, <xref rid="acn3276-bib-0011" ref-type="ref">11</xref>, <xref rid="acn3276-bib-0018" ref-type="ref">18</xref> and we describe a third substitution in two patients, making this the most frequently mutated residue. The CpG dinucleotides in the codons for Arg1617 and Arg1872 are mutational hotspots (Fig. <xref rid="acn3276-fig-0001" ref-type="fig">1</xref>B). Recurrence in unrelated patients and absence from unaffected individuals (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org">http://exac.broadinstitute.org</ext-link>) provides strong evidence that these mutations are pathogenic. Our data demonstrate that these mutations result in impaired channel inactivation that underlies neuronal hyperexcitability and seizures.</p>
    </sec>
    <sec id="acn3276-sec-0006">
      <title>Material and Methods</title>
      <sec id="acn3276-sec-0007">
        <title>Clinical exome sequencing</title>
        <p>The c.5615G&gt;T mutation (p.Arg1872Leu) in Case 1 was identified by whole exome sequencing at the Genomic Medicine Institute at the Cleveland Clinic (Cleveland, OH, USA). The c.5615G&gt;T mutation (p.Arg1872Leu) in Case 2 was identified by whole exome sequencing at the Johns Hopkins Medical Institute (Baltimore, MD, USA). The c.5615G&gt;A mutation (p.Arg1872Gln) in Case 3 was identified in the clinical exome sequencing laboratory at Radboud University (Nijmegen, the Netherlands).</p>
      </sec>
      <sec id="acn3276-sec-0008">
        <title>Standard protocol approvals, registrations, and patient consents</title>
        <p>An institutional review board (IRB) approval was obtained and the parent or legal guardian of each patient gave informed consent.</p>
      </sec>
      <sec id="acn3276-sec-0009">
        <title>Siteâdirected mutagenesis of the Na<sub>v</sub>1.6 cDNA and Câterminal constructs</title>
        <p>The amino acid substitutions p.Arg1617Gln, p.Arg1872Leu, and p.Arg1872Trp were introduced into the tetrodotoxin (TTX)âresistant derivative of the fullâlength Na<sub>v</sub>1.6 cDNA clone<xref rid="acn3276-bib-0019" ref-type="ref">19</xref> as described previously.<xref rid="acn3276-bib-0004" ref-type="ref">4</xref> Siteâdirected mutagenesis was carried out with the QuikChange II XL kit (Agilent Technologies, Santa Clara, CA, USA). The entire 6âkb open reading frame was sequenced to confirm the absence of other mutations.</p>
        <p>The pHAâNa<sub>v</sub>1.6âCT cDNA construct containing the 213 amino acid Câterminal domain of Na<sub>v</sub>1.6 with an Nâterminal HA epitope tag<xref rid="acn3276-bib-0020" ref-type="ref">20</xref> was kindly provided by Dr. David Ornitz, Washington University. The substitution p.Arg1872Trp was introduced as above and the open reading frame was completely sequenced.</p>
      </sec>
      <sec id="acn3276-sec-0010">
        <title>Plasmids encoding sodium channelâinteracting proteins</title>
        <p>The sodium channel <italic>Î²</italic> subunit cDNA construct pNav<italic>Î²</italic>1âEYFP was kindly provided by Dr. Jeanne Nerbonne.<xref rid="acn3276-bib-0021" ref-type="ref">21</xref> The fibroblast growth factor 14 cDNA construct pFGF14â1bâmyc tag was a gift from Dr. David Ornitz.<xref rid="acn3276-bib-0022" ref-type="ref">22</xref> Plasmids pG<italic>Î²</italic>
<sub>2</sub>IRESâYFP and pG<italic>Î³</italic>
<sub>3</sub>IRESâcyan encoding the Gâprotein subunits G<italic>Î²</italic>
<sub>2</sub> and G<italic>Î³</italic>
<sub>3</sub> were kindly provided by Dr. Massimo Mantegazza.<xref rid="acn3276-bib-0023" ref-type="ref">23</xref>
</p>
      </sec>
      <sec id="acn3276-sec-0011">
        <title>Cell culture</title>
        <p>DRGâneuronâderived ND7/23 cells (Sigma Aldrich, St. Louis, MO, USA) were grown in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air at 37Â°C in Dulbecco's Modified Eagle's Medium (DMEM, 1X) supplemented with 10% fetal bovine serum (FBS), nonâessential amino acids (NEAA) and sodium pyruvate. Cells were plated onto Petri dishes 48 h prior to transfection and transfected for 5 h in nonâsupplemented DMEM using Lipofectamine 3000 according to the manufacturer's instruction (Life Technologies, Carlsbad, CA, USA) with 5 <italic>Î¼</italic>g of Na<sub>v</sub>1.6 <italic>Î±</italic> subunit cDNA and 0.5 <italic>Î¼</italic>g of the fluorescent mâVenus bioreporter. Electrophysiological recordings of fluorescent cells were made 48 h after transfection.</p>
      </sec>
      <sec id="acn3276-sec-0012">
        <title>Electrophysiology</title>
        <p>Recordings were carried out in the presence of 500 nmol/L TTX to block endogenous sodium currents in the neuronâderived ND7/23 cells. Currents were recorded using the wholeâcell configuration of the patch clamp recording technique as described previously.<xref rid="acn3276-bib-0024" ref-type="ref">24</xref> The intracellular recording solution contained (in mmol/L): 140 CsF, 2 MgCl<sub>2</sub>, 1 EGTA, 10 HEPES, 4 Na<sub>2</sub>ATP, 0.3 NaGTP (pH adjusted to 7.3 with CsOH, osmolarity adjusted to 290 mOsm with sucrose). Cultured ND7/23 cells were bathed in solution containing (in mmol/L): 130 NaCl, 4 KCl, 1 CaCl<sub>2</sub>, 5 MgCl<sub>2</sub>, 5 HEPES, 5 Glucose (pH adjusted to 7.4 with NaOH, osmolarity adjusted to 300 mOsm with sucrose). Experiments were performed at room temperature (20â22Â°C). After establishing whole cell, a minimum series resistance compensation of 75% was applied. Capacitive and leak currents were subtracted using the P/Nâ4 protocol for all experiments, except steadyâstate inactivation protocols. The currentâvoltage relationship was determined using a 100âmsec voltage pulse from â80 to +70 mV in steps of 5 mV from a holding potential of â120 mV at 2 sec intervals. Conductance as a function of voltage was derived from the currentâvoltage relationship and fitted by a Boltzmann function as described previously.<xref rid="acn3276-bib-0024" ref-type="ref">24</xref> Decays of macroscopic currents were fitted to a single exponential function and time constants were determined.<xref rid="acn3276-bib-0025" ref-type="ref">25</xref> For steadyâstate inactivation, neurons were held at â120 mV and test potentials from â115 mV to â10 mV for 1 sec at 5 mV increments were applied. The second pulse to â10 mV for 40 msec was used to assess channel availability. Currents during the second pulse were normalized for each cell with the largest current as 1.0 and fit to the Boltzmann function. For recovery from inactivation, neurons were held at â120 mV and depolarized to a test potential of 0 mV for 1 sec to inactivate the Na channels. Recovery was determined at times between 1 msec and 60 sec at a test potential of â90 mV. A 40 msec pulse to â10 mV was subsequently applied to assess the extent of channel recovery. For each cell, current amplitudes during this test pulse were normalized so that the largest current during the conditioning potential was 1.0. Data were fit to a double exponential function:<disp-formula id="acn3276-disp-0001"><mml:math xmlns:mml="https://jats.nlm.nih.gov/ns/archiving/1.0/" id="nlm-math-1"><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>â</mml:mo><mml:mo>exp</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mo>â</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>â</mml:mo><mml:mo>exp</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mo>â</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
        <p>where <italic>A</italic>
<sub>1</sub> and <italic>A</italic>
<sub>2</sub> are the coefficients for the fast and slow exponentials, <italic>t</italic> is the time (in msec), and <italic>Æ¬</italic>
<sub>1</sub> and <italic>Æ¬</italic>
<sub>2</sub> are the fast and slow time constants, respectively.</p>
      </sec>
      <sec id="acn3276-sec-0013">
        <title>Coimmunoprecipitation and western blotting</title>
        <p>HEK293 cells were transfected with 3 <italic>Î¼</italic>g of cDNA encoding the Câterminal domain of Na<sub>v</sub>1.6 and 3 <italic>Î¼</italic>g of the test construct. Cell extracts were prepared and immunoprecipitated as described previously.<xref rid="acn3276-bib-0026" ref-type="ref">26</xref> Cells were lysed in 1 mL of buffer containing 20 mmol/L TrisâHCl, pH 7.5, 137 mmol/L NaCl, and 1% NPâ40 with protease inhibitors (Roche complete mini, EDTAâfree, Indianapolis, IN, USA). Lysates were incubated with 20 <italic>Î¼</italic>L antiâHA antibodyâcoated agarose beads (scâ7392AC, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4Â°C. Immune complexes on the beads were washed four times and eluted by boiling in 2X electrophoresis sample buffer at 95Â°C for 5 min. Western blotting was carried out as described previously.<xref rid="acn3276-bib-0027" ref-type="ref">27</xref> Blots were immunostained with rabbit polyclonal antiâHA (H6908, Sigma Aldrich), rabbit polyclonal antiâGFP (G1544, Sigma Aldrich), rabbit polyclonal antiâmyc (C3956, Sigma Aldrich), or rabbit polyclonal antiâG<italic>Î²</italic>
<sub>2</sub> (scâ380, Santa Cruz Biotechnology).</p>
      </sec>
    </sec>
    <sec id="acn3276-sec-0014">
      <title>Results</title>
      <sec id="acn3276-sec-0015">
        <title>Clinical features of three patients with mutations of arginine 1872</title>
        <p>The clinical features of three new cases are summarized in Table <xref rid="acn3276-tbl-0001" ref-type="table-wrap">1</xref>. All three patients were born after fullâterm pregnancies. Clinical exome sequencing identified the heterozygous mutation c.5615G&gt;T resulting in the novel amino acid substitution p.Arg1872Leu in patients 1 and 2. Patient 3 carried the <italic>SCN8A</italic> mutation c.5615G&gt;A resulting in the amino acid substitution p.Arg1872Gln. None of the mutations were present in either parent, demonstrating de novo origin.</p>
        <table-wrap id="acn3276-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Clinical features of three new patients with amino acid substitution of arginine residue 1872</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Patient (sex)</td>
                <td align="left" rowspan="1" colspan="1">1 (F)</td>
                <td align="left" rowspan="1" colspan="1">2 (F)</td>
                <td align="left" rowspan="1" colspan="1">3 (M)</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Amino acid substitution</td>
                <td align="left" rowspan="1" colspan="1">p.Arg1872Leu</td>
                <td align="left" rowspan="1" colspan="1">p.Arg1872Leu</td>
                <td align="left" rowspan="1" colspan="1">p.Arg1872Gln</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Seizure onset</td>
                <td align="left" rowspan="1" colspan="1">2 weeks</td>
                <td align="left" rowspan="1" colspan="1">6 weeks</td>
                <td align="left" rowspan="1" colspan="1">4 months</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Current age</td>
                <td align="left" rowspan="1" colspan="1">17 years</td>
                <td align="left" rowspan="1" colspan="1">1.5 years</td>
                <td align="left" rowspan="1" colspan="1">2 years</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Seizure types</td>
                <td align="left" rowspan="1" colspan="1">GTC</td>
                <td align="left" rowspan="1" colspan="1">GTC with apnea</td>
                <td align="left" rowspan="1" colspan="1">GTC, A, T with bradycardia, SE</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Development and motor abnormalities</td>
                <td align="left" rowspan="1" colspan="1">Walking at 12â15 months, then regression with hypotonia progressing to hypertonia and quadriplegia</td>
                <td align="left" rowspan="1" colspan="1">Sat 12 months, hypotonia</td>
                <td align="left" rowspan="1" colspan="1">Speech arrest 10 months, sat 13 months, walked 16 months</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Intellectual disability</td>
                <td align="left" rowspan="1" colspan="1">Severe</td>
                <td align="left" rowspan="1" colspan="1">Moderate</td>
                <td align="left" rowspan="1" colspan="1">Severe</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">EEG</td>
                <td align="left" rowspan="1" colspan="1">Generalized slowing, severe diffuse encephalopathy</td>
                <td align="left" rowspan="1" colspan="1">Normal</td>
                <td align="left" rowspan="1" colspan="1">Diffuse encephalopathy</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">MRI</td>
                <td align="left" rowspan="1" colspan="1">Cerebella and cerebral atrophy</td>
                <td align="left" rowspan="1" colspan="1">Normal</td>
                <td align="left" rowspan="1" colspan="1">Bilateral flat insular cortex</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Drug response</td>
                <td align="left" rowspan="1" colspan="1">PHT and VNS partially effective</td>
                <td align="left" rowspan="1" colspan="1">TPM and LEV temporarily effective, OXC, LTG, VPA, and CLN effective</td>
                <td align="left" rowspan="1" colspan="1">ZNS and LEV temporarily effective, PHT and LEV effective</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="acn3276-note-0001">
              <p>A, absence; CLN, clonazepam; GTC, generalized tonicâclonic; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; SE, status epilepticus; T, tonic, TPM, topiramate; VNS, vagus nerve stimulator; VPA, valproate; ZNS, zonisamide.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>The features of these patients are consistent with the recently described clinical spectrum of <italic>SCN8A</italic> encephaloâpathy.<xref rid="acn3276-bib-0001" ref-type="ref">1</xref> Two patients exhibited very early onset at 2 and 6 weeks of age. Sodium channel blockers were partially effective (Table <xref rid="acn3276-tbl-0001" ref-type="table-wrap">1</xref>). Detailed clinical histories are provided as an Appendix.</p>
      </sec>
      <sec id="acn3276-sec-0016">
        <title>Functional effects of mutations in arginine residue 1872</title>
        <p>Arginine residue 1872 is located near the center of the cytoplasmic Câterminal domain of Na<sub>v</sub>1.6 (Fig. <xref rid="acn3276-fig-0001" ref-type="fig">1</xref>A). This site was implicated in direct interaction with the inactivation gate of the channel, mediated by interaction between positively and negatively charged residues.<xref rid="acn3276-bib-0028" ref-type="ref">28</xref>, <xref rid="acn3276-bib-0029" ref-type="ref">29</xref> Loss of the positive charge of arginine residue 1872 is therefore predicted to impair channel inactivation.</p>
        <p>Patient mutations substituting leucine, glutamine, or tryptophan for arginine 1872 were introduced into the fullâlength Na<sub>v</sub>1.6 cDNA, which was transfected into the neuronâderived cell line ND7/23. Representative currents from ND7/23 cells transfected with wildâtype (WT) and mutant Na<sub>v</sub>1.6 channels are shown in Figure <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>A. Peak current density was elevated for p.Arg1872Trp, but was not significantly changed for p.Arg1872Leu or p.Arg1872Gln (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>B, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>). To determine the kinetics of open state inactivation, macroscopic current decay was fit to single exponential functions and the fast time constant (<italic>Ï</italic>
<sub>fast</sub>) was plotted as a function of voltage. Transition from open state to the inactivated state was significantly delayed by all three mutations (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>C), consistent with prediction. The slowing of fast inactivation is evident when the peaks of the current traces are aligned so that inactivation kinetics can be compared directly (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>D).</p>
        <fig fig-type="Figure" xml:lang="en" id="acn3276-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Biophysical effects of missense mutations at residue Arg1872 in Na<sub>v</sub>1.6. (A) Representative traces of families of Na currents from <styled-content style="fixed-case">ND</styled-content>7/23 cells transfected with the indicated Na<sub>v</sub>1.6 <styled-content style="fixed-case">cDNA</styled-content>s. (B) Averaged currentâvoltage (IâV) relation for cells expressing <styled-content style="fixed-case">WT</styled-content> and mutant Na<sub>v</sub>1.6. Peak currents were normalized to cell capacitance. (C) Average fast time constant obtained from single exponential fits to macroscopic current decays as a function of voltage (mV). (D) Representative traces of normalized currents evoked by a â20 mV stimulus from a holding potential of â120 mV illustrate delays in macroscopic current decay. (E) Representative normalized current traces recorded during a 100âmsec depolarizing pulse from â120 mV to 0 mV illustrating the presence of elevated persistent sodium current for p.Arg1872Leu. (F) Voltage dependence of channel activation. (G) Voltage dependence of steadyâstate inactivation. Smooth lines correspond to the least squares fit when average data were fit to a single Boltzmann equation. Data are mean Â± SEM. Statistical significance: *<italic>P</italic> &lt; 0.05. Black, wild type; red, p.Arg1872Leu; orange, p.Arg1872Gln; green, p.Arg1872Trp.</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="ACN3-3-114-g002"/>
        </fig>
        <table-wrap id="acn3276-tbl-0002" xml:lang="en" orientation="portrait" position="float">
          <label>Table 2</label>
          <caption>
            <p>Biophysical properties of <styled-content style="fixed-case"><styled-content style="italic-in-any-context">SCN8A</styled-content></styled-content> mutants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" rowspan="2" valign="top" colspan="1"/>
                <th align="char" rowspan="2" valign="top" colspan="1">Peak Current (pA/pF)</th>
                <th align="char" rowspan="2" valign="top" colspan="1">
<italic>n</italic>
</th>
                <th align="char" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Persistent</th>
                <th align="char" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Activation (mV)</th>
                <th align="char" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Inactivation (mV)</th>
              </tr>
              <tr style="border-bottom:solid 1px #000000">
                <th align="char" valign="top" rowspan="1" colspan="1">Ratio (Ip/Ipeak)</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>V</italic>
<sub>1/2</sub>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>k</italic>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>V</italic>
<sub>1/2</sub>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>k</italic>
</th>
                <th align="char" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">WT</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â101 Â± 15</td>
                <td align="char" char="." rowspan="1" colspan="1">30</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">1.8 Â± 0.4</td>
                <td align="char" char="." rowspan="1" colspan="1">8</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â13.3 Â± 0.5</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â7.3 Â± 0.2</td>
                <td align="char" char="." rowspan="1" colspan="1">30</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â61.5 Â± 1.1</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">8.0 Â± 0.4</td>
                <td align="char" char="." rowspan="1" colspan="1">19</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Arg1872Leu</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â89 Â± 15</td>
                <td align="char" char="." rowspan="1" colspan="1">10</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">4.7 Â± 1.5<xref ref-type="fn" rid="acn3276-note-0003">*</xref>
</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â17.9 Â± 1.2<xref ref-type="fn" rid="acn3276-note-0003">***</xref>
</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â6.7 Â± 0.4</td>
                <td align="char" char="." rowspan="1" colspan="1">10</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â60.0 Â± 1.3</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">7.5 Â± 0.8</td>
                <td align="char" char="." rowspan="1" colspan="1">10</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Arg1872Trp</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â153 Â± 27<xref ref-type="fn" rid="acn3276-note-0003">â </xref>
</td>
                <td align="char" char="." rowspan="1" colspan="1">21</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">2.7 Â± 0.4</td>
                <td align="char" char="." rowspan="1" colspan="1">11</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â14.2 Â± 1.4</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â7.2 Â± 0.4</td>
                <td align="char" char="." rowspan="1" colspan="1">21</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â61.4 Â± 1.6</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">8.6 Â± 0.6</td>
                <td align="char" char="." rowspan="1" colspan="1">18</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Arg1872Gln</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â135 Â± 35</td>
                <td align="char" char="." rowspan="1" colspan="1">8</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">1.6 Â± 0.5</td>
                <td align="char" char="." rowspan="1" colspan="1">17</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â19.2 Â± 0.8***</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â5.8 Â± 0.5<xref ref-type="fn" rid="acn3276-note-0003">**</xref>
</td>
                <td align="char" char="." rowspan="1" colspan="1">8</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â53.5 Â± 0.5***</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">7.9 Â± 0.3</td>
                <td align="char" char="." rowspan="1" colspan="1">18</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Arg1617Gln</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â73 Â± 15</td>
                <td align="char" char="." rowspan="1" colspan="1">10</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">5.5 Â± 1.7<xref ref-type="fn" rid="acn3276-note-0003">*</xref>
</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â17.1 Â± 2.0<xref ref-type="fn" rid="acn3276-note-0003">*</xref>
</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â7.8 Â± 0.3</td>
                <td align="char" char="." rowspan="1" colspan="1">10</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">â52.6 Â± 1.7<xref ref-type="fn" rid="acn3276-note-0003">***</xref>
</td>
                <td align="char" char="Â±" rowspan="1" colspan="1">12.5 Â± 0.6***</td>
                <td align="char" char="." rowspan="1" colspan="1">8</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="acn3276-note-0003">
              <p>Values represent mean Â± SEM, <italic>n</italic> = number of cells, <italic>V</italic>
<sub>1/2</sub>, voltage of halfâmaximal activation or inactivation; <italic>k</italic>, slope factor. Significance was determined by unpaired Student's <italic>t</italic> test: *<italic>P</italic> &lt; 0.05 versus WT, **<italic>P</italic> &lt; 0.005 versus WT, ***<italic>P</italic> &lt; 0.0005 versus WT, or MannâWhitney test, â <italic>P</italic> &lt; 0.05 versus WT.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>At 100 msec after stimulus, p.Arg1872Leu exhibited elevated persistent current normalized to the peak of the macroscopic current (<italic>I</italic>
<sub>persistent</sub>/<italic>I</italic>
<sub>peak</sub>) (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>E, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>). Ramp currents evoked using a slow ramp stimulus did not differ from WT for any of the mutants (data not shown).</p>
        <p>Analysis of steadyâstate kinetics demonstrates that p.Arg1872Leu and p.Arg1872Gln cause a small but significant hyperpolarizing shift in the voltage dependence of activation (<italic>P</italic> &lt; 0.05) (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>F, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>). In addition, p.Arg1872Gln caused a depolarizing shift in steadyâstate inactivation (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>G, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>). The values for the slope (<italic>k</italic>) were unchanged.</p>
      </sec>
      <sec id="acn3276-sec-0017">
        <title>Functional effects of the recurrent mutation p.Arg1617Gln</title>
        <p>Arginine residue 1617 is the outermost positively charged residue in the voltageâresponsive transmembrane segment DIVâS4 and is implicated in coupling of channel activation with subsequent inactivation.</p>
        <p>Representative currents from ND7/23 cells transfected with the p.Arg1617Gln mutant of Na<sub>v</sub>1.6 are shown in Figure <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>A. Peak current densities for p.Arg1617Gln were not different from WT (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>B). A profound change in the kinetics of transition from open state to the inactivated state was observed. At voltages above â20 mV, the WT channel exhibits faster decay time constants with increasing depolarizing voltage steps, but this response is missing for p.Arg1617Gln (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>C). Sample traces reveal the striking difference in current decay between WT and mutant channel (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>D). The apparent uncoupling of activation to fast inactivation likely accounts for the large increase in persistent current from 1% of peak transient current for the WT channels to 6% of peak transient current for the p.Arg1617Gln channels (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>E). The elevation of persistent current is evident in the ratio of persistent current to peak current for p.Arg1617Gln (Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="acn3276-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Biophysical effects of the missense mutation p.Arg1617Gln in Na<sub>v</sub>1.6. (A) Representative traces of families of Na currents from <styled-content style="fixed-case">ND</styled-content>7/23 cells transfected with the indicated Na<sub>v</sub>1.6 <styled-content style="fixed-case">cDNA</styled-content>. (B) Averaged currentâvoltage (IâV) relation for cells expressing <styled-content style="fixed-case">WT</styled-content> and p.Arg1617Gln. Peak currents were normalized to cell capacitance. (C) Average fast time constant obtained from single exponential fits to macroscopic current decays as a function of voltage (mV). (D) Representative traces of normalized currents evoked by a depolarizing step to â20 mV from a holding potential of â120 mV illustrate significant delay in macroscopic current decay in p.Arg1617Gln (blue) compared to <styled-content style="fixed-case">WT</styled-content> (black). (E) Representative normalized current traces recorded during a 100âmsec depolarizing pulse from â120 mV to 0 mV illustrating the presence of elevated persistent sodium current. (F) Voltage dependence of channel activation. (G) Voltage dependence of steadyâstate inactivation. (H). Representative inactivation traces recorded after a 1âsec prepulse of â100 mV (larger amplitude) and â45 mV (smaller amplitude). Smooth lines in (F) and (G) correspond to the least squares fit when average data were fit to a single Boltzmann equation. Data are mean Â± SEM. Statistical significance: *<italic>P</italic> &lt; 0.05. Black, wild type; blue, p.Arg1617Gln.</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="ACN3-3-114-g003"/>
        </fig>
        <p>The inactivation parameters for p.Arg1617Gln were significantly shifted in the depolarizing direction and the value of the slope was increased, demonstrating disruption in the normal process of channel inactivation (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>G, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>). The difference in the extent of inactivation at â45 mV is shown in Figure <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>H. There was also a small hyperpolarizing shift in the voltage dependence of activation (Fig. <xref rid="acn3276-fig-0003" ref-type="fig">3</xref>F, Table <xref rid="acn3276-tbl-0002" ref-type="table-wrap">2</xref>).</p>
      </sec>
      <sec id="acn3276-sec-0018">
        <title>Protein interactions with the Câterminal domain of Na<sub>v</sub>1.6</title>
        <p>In addition to its role in channel inactivation, the Câterminal domain of Na<sub>v</sub>1.6 interacts with several proteins that regulate channel trafficking or activity.<xref rid="acn3276-bib-0020" ref-type="ref">20</xref>, <xref rid="acn3276-bib-0023" ref-type="ref">23</xref>, <xref rid="acn3276-bib-0030" ref-type="ref">30</xref> To determine whether mutations at Arg1872 disrupt these interactions, we tested the effect of the p.Arg1872Trp mutation with substitution of the large uncharged tryptophan residue.</p>
        <p>HEK cells were cotransfected with cDNAs encoding the HAâtagged WT or mutant Câterminal fragment of Na<sub>v</sub>1.6 and cDNAs encoding the Gâprotein subunits G<italic>Î²</italic>
<sub>2</sub> and G<italic>Î³</italic>
<sub>3</sub>. Lysates were incubated with antiâHAâcoated beads and bound proteins were eluted and examined by western blotting. The yield of G<italic>Î²</italic>
<sub>2</sub> was comparable with mutant and WT Câterminus (Fig. S1A). Similarly, the mutation did not impair binding of the sodium channel <italic>Î²</italic>1 subunit (Fig. S1B) and the fibroblast growth factor isoform FGF14b (Fig. S1C).</p>
      </sec>
    </sec>
    <sec id="acn3276-sec-0019">
      <title>Discussion</title>
      <p>Unlike protein termination mutations, the pathogenic impact of missense mutations is difficult to predict without functional tests. Due in part to the multiple intramolecular interactions within the sodium channel <italic>Î±</italic> subunit,<xref rid="acn3276-bib-0031" ref-type="ref">31</xref>, <xref rid="acn3276-bib-0032" ref-type="ref">32</xref> substitution of a single amino acid often has multiple effects on sodium channel function.</p>
      <sec id="acn3276-sec-0020">
        <title>Mutations at Arg1872 and Arg1617 impair channel inactivation by different intramolecular mechanisms</title>
        <p>The three allelic mutations that eliminate the positively charged residue Arg1872 from the Câterminus of Na<sub>v</sub>1.6 all result in a significant delay in transition from the open state to the inactivated state. This observation is consistent with previous studies demonstrating a direct role of the Câterminal domain in fast inactivation.<xref rid="acn3276-bib-0029" ref-type="ref">29</xref>, <xref rid="acn3276-bib-0033" ref-type="ref">33</xref> Interaction of the Câterminus of sodium channel Na<sub>v</sub>1.5 with its inactivation gate was shown to stabilize the inactivated state.<xref rid="acn3276-bib-0031" ref-type="ref">31</xref>, <xref rid="acn3276-bib-0034" ref-type="ref">34</xref> Exchange of Câterminal domains between sodium channels Na<sub>v</sub>1.2, Na<sub>v</sub>1.5, and Na<sub>v</sub>1.6 results in partial transfer of inactivation properties.<xref rid="acn3276-bib-0028" ref-type="ref">28</xref>, <xref rid="acn3276-bib-0033" ref-type="ref">33</xref> The interaction between the Câterminus and the inactivation gate appears to involve electrostatic interactions, since inactivation of Na<sub>v</sub>1.2 was slowed by reversing the charge of Glu1880 (corresponding to Glu1870 in Na<sub>v</sub>1.6) by replacement with lysine.<xref rid="acn3276-bib-0029" ref-type="ref">29</xref> These data support the view that loss of the positively charged residue arginine 1872 destabilizes interaction with the inactivation gate and delays entry into the inactivated state. This is predicted to increase the fraction of channels that can reopen during sustained depolarization, resulting in increased channel activity and epileptogenic persistent current. The different effects on current density and channel kinetics of these allelic substitutions can be related to the chemical structure of the substituted residue. Substitution of the corresponding arginine residue of Na<sub>v</sub>1.2 by leucine or glutamine also results in epileptic encephalopathy.<xref rid="acn3276-bib-0018" ref-type="ref">18</xref>, <xref rid="acn3276-bib-0035" ref-type="ref">35</xref>
</p>
        <p>Replacement of arginine residue 1617 by glutamine appears to interfere with the initiation of fast inactivation from the open state. Arginine 1617 is the outermost charged residue in the S4 voltage sensor segment of DIV, which is thought to initiate channel inactivation through a conformational change.<xref rid="acn3276-bib-0036" ref-type="ref">36</xref> In the crystal structure of the single domain bacterial channel NaChBac, the outermost arginine of S4 interacts with the negatively charged glutamate residue in segment S1 in the open state, and the negatively charged aspartate in segment S2 in the closed state.<xref rid="acn3276-bib-0037" ref-type="ref">37</xref> Loss of the positively charged arginine by p.Arg1617Gln would disrupt these electrostatic interactions, consistent with the observed defect in coupling of activation and inactivation (Fig. <xref rid="acn3276-fig-0002" ref-type="fig">2</xref>C). We also observed a small depolarizing shift in the voltage dependence of inactivation due to p.Arg1617Gln. The alterations in <italic>V</italic>
<sub>1/2</sub> and the slope of the steadyâstate inactivation curve are consistent with impaired allosteric interactions between the DIVâS1 sensor segment that initiates activation and the DIVâS4 sensor segment that initiates inactivation.</p>
      </sec>
      <sec id="acn3276-sec-0021">
        <title>Comparison with previously described pathogenic mutations of <italic>SCN8A</italic>
</title>
        <p>Through different effects on intramolecular interactions, the recurrent mutations of Arg1617 and Arg1872 lead to disruption of channel inactivation in 15 independent patients. Along with the original mutation, p.Asn1768Asp, this work indicates that impaired inactivation of Na<sub>v</sub>1.6 is the predominant pathogenic mechanism in EIEE13. A contrasting mechanism, premature channel activation, was observed for two mutations located in transmembrane segments of domain II, pThr767Ile and p.Asn984Lys.<xref rid="acn3276-bib-0006" ref-type="ref">6</xref>, <xref rid="acn3276-bib-0009" ref-type="ref">9</xref> The other two functionally characterized <italic>SCN8A</italic> mutations caused reduction in peak current density (p.Gly1451Ser)<xref rid="acn3276-bib-0006" ref-type="ref">6</xref> and decreased protein stability (p.Arg223Gly)<xref rid="acn3276-bib-0007" ref-type="ref">7</xref>; the role of these effects in neuronal hyperexcitability is unclear.</p>
      </sec>
      <sec id="acn3276-sec-0022">
        <title>Functional alterations of <italic>SCN8A</italic> and clinical severity</title>
        <p>There is considerable heterogeneity in the clinical features of patients with mutation of Arg1872, even among patients with identical mutations (Table S1). With respect to age of onset, intellectual disability, and motor function, the least severe course of disease was seen in patients with p.Arg1872Gln. More severe impairment, extending to inability to initiate purposeful movement and one case of SUDEP, was seen in the patients with p.Arg1872Leu and p.Arg1872Trp. p.Arg1872Gln led to bradycardia in patient 3, consistent with our recent observation of cardiac arrhythmia in a mouse model of EIEE13 (Frasier et al., unpubl. ms.). The expression of Na<sub>v</sub>1.6 in cardiomyocytes<xref rid="acn3276-bib-0038" ref-type="ref">38</xref> may contribute to risk of SUDEP in EIEE13 patients.</p>
        <p>The five previously described patients with the p.Arg1617Gln mutation also displayed considerable clinical heterogeneity, with seizure onset between 3 and 12 months of age, and variation in drug responses.<xref rid="acn3276-bib-0005" ref-type="ref">5</xref> One patient became nonambulatory and one had SUDEP.</p>
        <p>The features of patients with mutations of Arg1617 and Arg1872 exhibit considerable overlap, consistent with their shared effect on channel inactivation. Seizure onset within the first month is more common in patients with mutations of Arg1872, but there is no difference in the proportion of patients whose seizures are refractory to drug treatment, or in the frequency of nonambulatory status. The variation within each group appears as great as the difference between groups. Variation between patients with identical mutations may be accounted for by differences in genetic background, including genetic variation in other channel genes,<xref rid="acn3276-bib-0039" ref-type="ref">39</xref> as well as stochastic variation during the development of the nervous system. The course of drug treatment itself may influence clinical outcome.<xref rid="acn3276-bib-0005" ref-type="ref">5</xref>
</p>
      </sec>
      <sec id="acn3276-sec-0023">
        <title>Development of targeted therapy for EIEE13</title>
        <p>Sodium channel blockers have some efficacy in this patient population, presumably by countering the effects of gainâofâfunction mutations causing channel hyperactivity (Tables <xref rid="acn3276-tbl-0001" ref-type="table-wrap">1</xref>, S1). This beneficial response contrasts to the response of patients with Dravet syndrome (EIEE6), in which the effects of lossâofâfunction mutations of <italic>SCN1A</italic> are exacerbated by administration of sodium channel blockers. Unfortunately, response to antiepileptic drugs in EIEE13 is often transient. The development of Na<sub>v</sub>1.6âspecific channel blockers has been hampered by the structural similarity among members of the voltageâgated sodium channel gene family. A mouse epilepsy model with impaired inactivation of <italic>Scn2a</italic> was effectively treated with the cardiac drugs ranolazine and GS967, which are somewhat selective inhibitors of persistent sodium current.<xref rid="acn3276-bib-0040" ref-type="ref">40</xref> Activation of potassium channels to compensate for sodium channel hyperactivity is another potential approach.</p>
        <p>Recurrent missense mutations at <italic>SCN8A</italic> residues Arg1617 and Arg1872 result in elevated activity of Nav1.6 as a result of impaired channel inactivation. This work confirms the important role of gainâofâfunction mutations in EIEE13 and demonstrates that impaired channel inactivation is a prominent pathogenic mechanism.</p>
      </sec>
    </sec>
    <sec id="acn3276-sec-0025">
      <title>Author Contributions</title>
      <p>The study was designed by J. L. W., M. H. M., and M. K. P. Clinical descriptions were provided by C. A. H., A. S., T. M., S. P., and R. D. M. Experimental data were collected by J. L. W., B. S. B., and J. A. H. and interpreted by J. L. W., B. S. B., J. A. H., M. K. P., and M. H. M. The manuscript was drafted by J. L. W., M. H. M., and M. K. P., and revised by all authors.</p>
    </sec>
    <sec id="acn3276-sec-0026">
      <title>Conflict of Interest</title>
      <p>None declared.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <caption>
          <p>
<bold>Figure S1.</bold> Substitution of tryptophan for Arg1872 of Nav1.6 does not impair coimmunoprecipitation of interacting proteins. (A) G<italic>Î²</italic>
<sub>2</sub>, (B) GFPâtagged sodium channel subunit <italic>Î²</italic>1, (C) mycâtagged FGF14b.</p>
          <p>
<bold>Table S1.</bold> Phenotypes of 10 individuals with amino acid substitutions at arginine residue 1872.</p>
        </caption>
        <media xlink:href="ACN3-3-114-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="acn3276-sec-0024">
      <title>Acknowledgments</title>
      <p>We thank the families for participating in this study. We are grateful to Sulayman DibâHajj and Stephen Waxman for providing the Na<sub>v</sub>1.6 cDNA. We also thank David Ornitz, Jeanne Nerbonne, and Massimo Mantegazza for cDNA constructs, and Jaclyn Walker and Rosie BuntonâStasyshyn for technical assistance and helpful discussions. This work was supported by the National Institutes of Health (NIH) grants R01âNS34509 (to M. H. M.) and R01âNS075157 (to M. K. P.). J. L. W. is recipient of a postdoctoral fellowship from the Dravet Syndrome Foundation.</p>
    </ack>
    <ref-list content-type="cited-references" id="acn3276-bibl-0001">
      <title>References</title>
      <ref id="acn3276-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Larsen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Gardella</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The phenotypic spectrum of <italic>SCN8A</italic> encephalopathy</article-title>. <source>Neurology</source>
<year>2015</year>;<volume>84</volume>:<fpage>480</fpage>â<lpage>489</lpage>.<pub-id pub-id-type="pmid">25568300</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Kong</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>
<italic>SCN8A</italic> mutations in Chinese children with early onset epilepsy and intellectual disability</article-title>. <source>Epilepsia</source>
<year>2015</year>;<volume>56</volume>:<fpage>431</fpage>â<lpage>438</lpage>.<pub-id pub-id-type="pmid">25785782</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Ohba</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Early onset epileptic encephalopathy caused by de novo <italic>SCN8A</italic> mutations</article-title>. <source>Epilepsia</source>
<year>2014</year>;<volume>55</volume>:<fpage>994</fpage>â<lpage>1000</lpage>.<pub-id pub-id-type="pmid">24888894</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Veeramah</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</string-name>, et al. <article-title>De novo pathogenic <italic>SCN8A</italic> mutation identified by wholeâgenome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP</article-title>. <source>Am J Hum Genet</source>
<year>2012</year>;<volume>90</volume>:<fpage>502</fpage>â<lpage>510</lpage>.<pub-id pub-id-type="pmid">22365152</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Wagnon</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Recurrent and nonârecurrent mutations of <italic>SCN8A</italic> in epileptic encephalopathy</article-title>. <source>Front Neurol</source>
<year>2015</year>;<volume>6</volume>:<fpage>104</fpage>.<pub-id pub-id-type="pmid">26029160</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Blanchard</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Willemsen</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>JB</given-names>
</string-name>, et al. <article-title>De novo gainâofâfunction and lossâofâfunction mutations of <italic>SCN8A</italic> in patients with intellectual disabilities and epilepsy</article-title>. <source>J Med Genet</source>
<year>2015</year>;<volume>52</volume>:<fpage>330</fpage>â<lpage>337</lpage>.<pub-id pub-id-type="pmid">25725044</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>de Kovel</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Brilstra</surname>
<given-names>EH</given-names>
</string-name>, et al. <article-title>Characterization of a de novo <italic>SCN8A</italic> mutation in a patient with epileptic encephalopathy</article-title>. <source>Epilepsy Res</source>
<year>2014</year>;<volume>108</volume>:<fpage>1511</fpage>â<lpage>1518</lpage>.<pub-id pub-id-type="pmid">25239001</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal">
<collab collab-type="authors">Epi4K Consortium, Epilepsy Phenome/Genome Project</collab>
, <string-name>
<surname>Allen</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>De novo mutations in epileptic encephalopathies</article-title>. <source>Nature</source>
<year>2013</year>;<volume>501</volume>:<fpage>217</fpage>â<lpage>221</lpage>.<pub-id pub-id-type="pmid">23934111</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Estacion</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Conravey</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>A novel de novo mutation of <italic>SCN8A</italic> (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy</article-title>. <source>Neurobiol Dis</source>
<year>2014</year>;<volume>69</volume>:<fpage>117</fpage>â<lpage>123</lpage>.<pub-id pub-id-type="pmid">24874546</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Singh</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jayapal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goyal</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Earlyâonset movement disorder and epileptic encephalopathy due to de novo dominant <italic>SCN8A</italic> mutation</article-title>. <source>Seizure</source>
<year>2015</year>;<volume>26</volume>:<fpage>69</fpage>â<lpage>71</lpage>.<pub-id pub-id-type="pmid">25799905</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Takahashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Okayama</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Electroclinical features of epileptic encephalopathy caused by <italic>SCN8A</italic> mutation</article-title>. <source>Pediatr Int</source>
<year>2015</year>;<volume>57</volume>:<fpage>758</fpage>â<lpage>762</lpage>.<pub-id pub-id-type="pmid">25951352</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Vaher</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Noukas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nikopensius</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>De novo <italic>SCN8A</italic> mutation identified by wholeâexome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders</article-title>. <source>J Child Neurol</source>
<year>2014</year>;<volume>29</volume>:<fpage>NP202</fpage>â<lpage>NP206</lpage>.<pub-id pub-id-type="pmid">24352161</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>O'Brien</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Meisler</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Sodium channel <italic>SCN8A</italic> (Nav1.6): properties and de novo mutations in epileptic encephaâlopathy and intellectual disability</article-title>. <source>Front Genet</source>
<year>2013</year>;<volume>4</volume>:<fpage>213</fpage>.<pub-id pub-id-type="pmid">24194747</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Caldwell</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Schaller</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Lasher</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Sodium channel Na(v)1.6 is localized at nodes of Ranvier, dendrites, and synapses</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2000</year>;<volume>97</volume>:<fpage>5616</fpage>â<lpage>5620</lpage>.<pub-id pub-id-type="pmid">10779552</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Lorincz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nusser</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Cellâtypeâdependent molecular composition of the axon initial segment</article-title>. <source>J Neurosci</source>
<year>2008</year>;<volume>28</volume>:<fpage>14329</fpage>â<lpage>14340</lpage>.<pub-id pub-id-type="pmid">19118165</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Dyment</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Tetreault</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beaulieu</surname>
<given-names>CL</given-names>
</string-name>, et al. <article-title>Wholeâexome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study</article-title>. <source>Clin Genet</source>
<year>2015</year>;<volume>88</volume>:<fpage>34</fpage>â<lpage>40</lpage>.<pub-id pub-id-type="pmid">25046240</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Rauch</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Graf</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Range of genetic mutations associated with severe nonâsyndromic sporadic intellectual disability: an exome sequencing study</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>380</volume>:<fpage>1674</fpage>â<lpage>1682</lpage>.<pub-id pub-id-type="pmid">23020937</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Carvill</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Heavin</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Yendle</surname>
<given-names>SC</given-names>
</string-name>, et al. <article-title>Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1</article-title>. <source>Nat Genet</source>
<year>2013</year>;<volume>45</volume>:<fpage>825</fpage>â<lpage>830</lpage>.<pub-id pub-id-type="pmid">23708187</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Herzog</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Cummins</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Ghassemi</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Distinct repriming and closedâstate inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons</article-title>. <source>J Physiol</source>
<year>2003</year>;<volume>551</volume>:<fpage>741</fpage>â<lpage>750</lpage>.<pub-id pub-id-type="pmid">12843211</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Laezza</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lampert</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kozel</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>FGF14 Nâterminal splice variants differentially modulate Nav1.2 and Nav1.6âencoded sodium channels</article-title>. <source>Mol Cell Neurosci</source>
<year>2009</year>;<volume>42</volume>:<fpage>90</fpage>â<lpage>101</lpage>.<pub-id pub-id-type="pmid">19465131</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Marionneau</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Carrasquillo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Norris</surname>
<given-names>AJ</given-names>
</string-name>, et al. <article-title>The sodium channel accessory subunit Navbeta1 regulates neuronal excitability through modulation of repolarizing voltageâgated K(+) channels</article-title>. <source>J Neurosci</source>
<year>2012</year>;<volume>32</volume>:<fpage>5716</fpage>â<lpage>5727</lpage>.<pub-id pub-id-type="pmid">22539834</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Laezza</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gerber</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>JY</given-names>
</string-name>, et al. <article-title>The FGF14(F145S) mutation disrupts the interaction of FGF14 with voltageâgated Na+ channels and impairs neuronal excitability</article-title>. <source>J Neurosci</source>
<year>2007</year>;<volume>27</volume>:<fpage>12033</fpage>â<lpage>12044</lpage>.<pub-id pub-id-type="pmid">17978045</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Mantegazza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Powell</surname>
<given-names>AJ</given-names>
</string-name>, et al. <article-title>Molecular determinants for modulation of persistent sodium current by Gâprotein betagamma subunits</article-title>. <source>J Neurosci</source>
<year>2005</year>;<volume>25</volume>:<fpage>3341</fpage>â<lpage>3349</lpage>.<pub-id pub-id-type="pmid">15800189</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Hargus</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Nigam</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bertram</surname>
<given-names>EH</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Evidence for a role of Nav1.6 in facilitating increases in neuronal hyperexcitability during epileptogenesis</article-title>. <source>J Neurophysiol</source>
<year>2013</year>;<volume>110</volume>:<fpage>1144</fpage>â<lpage>1157</lpage>.<pub-id pub-id-type="pmid">23741036</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Ko</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Lenkowski</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HC</given-names>
</string-name>, et al. <article-title>Modulation of Na(v)1.5 by beta1â and beta3âsubunit coâexpression in mammalian cells</article-title>. <source>Pflugers Arch</source>
<year>2005</year>;<volume>449</volume>:<fpage>403</fpage>â<lpage>412</lpage>.<pub-id pub-id-type="pmid">15455233</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>O'Brien</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Sharkey</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Vallianatos</surname>
<given-names>CN</given-names>
</string-name>, et al. <article-title>Interaction of voltageâgated sodium channel Nav1.6 (<italic>SCN8A</italic>) with microtubuleâassociated protein Map1b</article-title>. <source>J Biol Chem</source>
<year>2012</year>;<volume>287</volume>:<fpage>18459</fpage>â<lpage>18466</lpage>.<pub-id pub-id-type="pmid">22474336</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Wagnon</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Korn</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Parent</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Convulsive seizures and SUDEP in a mouse model of <italic>SCN8A</italic> epileptic encephalopathy</article-title>. <source>Hum Mol Genet</source>
<year>2015</year>;<volume>24</volume>:<fpage>506</fpage>â<lpage>515</lpage>.<pub-id pub-id-type="pmid">25227913</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goldin</surname>
<given-names>AL</given-names>
</string-name>. <article-title>Role of the amino and carboxy termini in isoformâspecific sodium channel variation</article-title>. <source>J Physiol</source>
<year>2008</year>;<volume>586</volume>:<fpage>3917</fpage>â<lpage>3926</lpage>.<pub-id pub-id-type="pmid">18565993</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Nguyen</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Goldin</surname>
<given-names>AL</given-names>
</string-name>. <article-title>Sodium channel carboxylâterminal residue regulates fast inactivation</article-title>. <source>J Biol Chem</source>
<year>2010</year>;<volume>285</volume>:<fpage>9077</fpage>â<lpage>9089</lpage>.<pub-id pub-id-type="pmid">20089854</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Spampanato</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kearney</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>de Haan</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interaction</article-title>. <source>J Neurosci</source>
<year>2004</year>;<volume>24</volume>:<fpage>10022</fpage>â<lpage>10034</lpage>.<pub-id pub-id-type="pmid">15525788</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Motoike</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Glaaser</surname>
<given-names>IW</given-names>
</string-name>, et al. <article-title>The Na+ channel inactivation gate is a molecular complex: a novel role of the COOHâterminal domain</article-title>. <source>J Gen Physiol</source>
<year>2004</year>;<volume>123</volume>:<fpage>155</fpage>â<lpage>165</lpage>.<pub-id pub-id-type="pmid">14744988</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Payandeh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Scheuer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</string-name>. <article-title>The crystal structure of a voltageâgated sodium channel</article-title>. <source>Nature</source>
<year>2011</year>;<volume>475</volume>:<fpage>353</fpage>â<lpage>358</lpage>.<pub-id pub-id-type="pmid">21743477</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Mantegazza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Scheuer</surname>
<given-names>T</given-names>
</string-name>. <article-title>Role of the Câterminal domain in inactivation of brain and cardiac sodium channels</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2001</year>;<volume>98</volume>:<fpage>15348</fpage>â<lpage>15353</lpage>.<pub-id pub-id-type="pmid">11742069</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Cormier</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Rivolta</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tateyama</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Secondary structure of the human cardiac Na+ channel C terminus: evidence for a role of helical structures in modulation of channel inactivation</article-title>. <source>J Biol Chem</source>
<year>2002</year>;<volume>277</volume>:<fpage>9233</fpage>â<lpage>9241</lpage>.<pub-id pub-id-type="pmid">11741959</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Baasch</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Huning</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gilissen</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Exome sequencing identifies a de novo SCN2A mutation in a patient with intractable seizures, severe intellectual disability, optic atrophy, muscular hypotonia, and brain abnormalities</article-title>. <source>Epilepsia</source>
<year>2014</year>;<volume>55</volume>:<fpage>e25</fpage>â<lpage>e29</lpage>.<pub-id pub-id-type="pmid">24579881</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Chanda</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Asamoah</surname>
<given-names>OK</given-names>
</string-name>, <string-name>
<surname>Bezanilla</surname>
<given-names>F</given-names>
</string-name>. <article-title>Coupling interactions between voltage sensors of the sodium channel as revealed by siteâspecific measurements</article-title>. <source>J Gen Physiol</source>
<year>2004</year>;<volume>123</volume>:<fpage>217</fpage>â<lpage>230</lpage>.<pub-id pub-id-type="pmid">14981134</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>YarovâYarovoy</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>DeCaen</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Westenbroek</surname>
<given-names>RE</given-names>
</string-name>, et al. <article-title>Structural basis for gating charge movement in the voltage sensor of a sodium channel</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2012</year>;<volume>109</volume>:<fpage>E93</fpage>â<lpage>E102</lpage>.<pub-id pub-id-type="pmid">22160714</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Noujaim</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Kaur</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Milstein</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>A null mutation of the neuronal sodium channel NaV1.6 disrupts action potential propagation and excitationâcontraction coupling in the mouse heart</article-title>. <source>FASEB J</source>
<year>2012</year>;<volume>26</volume>:<fpage>63</fpage>â<lpage>72</lpage>.<pub-id pub-id-type="pmid">21948246</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Klassen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Exome sequencing of ion channel genes reveals complex profiles confounding personal risk assessment in epilepsy</article-title>. <source>Cell</source>
<year>2011</year>;<volume>145</volume>:<fpage>1036</fpage>â<lpage>1048</lpage>.<pub-id pub-id-type="pmid">21703448</pub-id></mixed-citation>
      </ref>
      <ref id="acn3276-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal">
<string-name>
<surname>Anderson</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Hawkins</surname>
<given-names>NA</given-names>
</string-name>, et al. <article-title>Antiepileptic activity of preferential inhibitors of persistent sodium current</article-title>. <source>Epilepsia</source>
<year>2014</year>;<volume>55</volume>:<fpage>1274</fpage>â<lpage>1283</lpage>.<pub-id pub-id-type="pmid">24862204</pub-id></mixed-citation>
      </ref>
    </ref-list>
    <app-group>
      <app id="acn3276-app-0001" content-type="Appendix">
        <label>Appendix 1</label>
        <sec id="acn3276-sec-0027">
          <title>Clinical Descriptions</title>
          <p>Patient 1 experienced onset of generalized tonicâclonic seizures at 2 weeks of age that were refractory to treatment. A vagus nerve stimulator placed at 4 years of age reduced seizure frequency. Phenytoin reduced seizures, while carbamazepine, oxcarbazepine, lamotrigine, and topirimate were not effective. The patient was able to stand and walk with support at 12â15 months, but regressed and became nonambulatory, with generalized hypotonia at 5 years, contractures and spasticity at 13 years, and generalized hypertonia and spastic quadriplegia at 16 years. MRI revealed moderate cerebellar and mild cerebral atrophy. At 17 years, the patient is nonverbal with severe intellectual disability.</p>
          <p>Patient 2 experienced three prolonged seizures between 6 and 8 weeks of age. No abnormalities were detected by MRI or prolonged EEG. She responded well to levetiracetam and topiramate for 2 months before the return of generalized tonicâclonic seizures with stiffening of the extremities, twitching, and eye fluttering. Seizures were often accompanied by apnea and oxygen desaturation that resolved after the seizure. The patient was transitioned from levetiracetam and topirimate to oxcarbazepine and lamotrigine with good response until seizure frequency increased at 11 months of age. With the addition of valproate and clonazepam, seizures were well controlled from 12 months to the current age of 18 months. Developmental delay was mild until 11 months, when increased seizure frequency resulted in acute developmental regression including loss of head and trunk control, loss of eye contact, and placement of a feeding tube. Control of seizures at 12 months of age resulted in improvement including regained eye contact and head control and the ability to sit with support.</p>
          <p>Patient 3 experienced seizures beginning at 4 months of age, usually during sleep or on waking, accompanied by tonic posturing of the head and severe bradycardia, followed by flexing of the arms and extension of the legs. Levetiracetam and zonisamide controlled seizures for 1 month before daily seizures reoccurred. Elevating zonisamide reduced seizures but caused severe (nonepileptic) encephalopathy, reversible upon lowering zonisamide. Addition of phenytoin reduced seizures to â¤1 per week. Gradual reduction of phenytoin resulted in increased seizure frequency. After an episode of status epilepticus at 19 months, seizure frequency stabilized at 5â10 per day, with development of asymmetric and absence seizures. Complete seizure control was obtained at 20 months with phenytoin and levetiracetam, and continued through the current age of 24 months. EEG was normal initially, but 6 weeks after seizure onset a hypofunctional area was detected in the left temporal lobe, from which abundant spikeâandâwave configurations and polyspikes emerged. EEGs at 6 and 9 months showed severe diffuse encephalopathy and multifocal epileptic discharges without hypsarrhythmia. MRI at 12 months showed a slightly underdeveloped cortex. Development was normal prior to seizure onset. Speech arrested at 10 months of age. While seizures were partially controlled between 11 and 17 months of age, he began sitting and walking with support. After status epilepticus at 19 months there was regression, but by 24 months he recovered unassisted walking and improved social interaction without improvement in development of speech.</p>
        </sec>
      </app>
    </app-group>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>